Clinical Trial: Phase 2 Study of MWN109 Tablet in Participants With Overweight or Obesity

U.S., Aug. 29 -- ClinicalTrials.gov registry received information related to the study (NCT07791524) titled 'Phase 2 Study of MWN109 Tablet in Participants With Overweight or Obesity' on Aug. 24.

Brief Summary: This is a phase II, multicenter, randomized, double-blind, placebo-controlled clinical trial to preliminarily evaluate the efficacy, safety, and PK of MWN109 tablets administered orally once daily in non-diabetic participants with overweight or obesity.

Approximately 240 participants will be enrolled. All participants will be stratified by gender (male or female) and then randomized 1:1:1:1:1 to 5 treatment groups, with approximately 48 participants per group. All treatment groups will implement dose titration to achieve the target...